At 4 weeks post-surgery, the patient's anterior tibialis and quadriceps strength had improved from 2 to 3 out of 5 preoperatively to 4 out of 5. Routine fluoroscopy and high-magnification ...

A qualitative matrix analysis allowed for the development of implementation strategies to improve the efficiency and effectiveness of the system. Researchers from the US identified an ideal system to ...

The project addresses a long-standing gap in the field: the lack of a clear human reference standard for muscle regeneration. A new research collaboration between muscular dystrophy organizations aims ...

The authors argue that the long-held label of "uniformly lethal" may no longer be appropriate and can inadvertently bias clinical decision-making. Homozygous achondroplasia is traditionally ...

Fenebrutinib demonstrated noninferiority to ocrelizumab in patients with PPMS, a population with limited treatment options. Genentech has reported that fenebrutinib reduced relapse rates in relapsing ...

Inebilizumab-cdon (Uplizna ®) has received US Food and Drug Administration (FDA) approval for the treatment of adults with generalized myasthenia gravis (MG) with antibodies against the acetylcholine ...

A banner welcomes delegates to the American College of Rheumatology’s 2025 conference in Chicago (Photo by Larry Luxner) The American College of Rheumatology awarded its 2025 Presidential Gold Medal ...

The recommendations were based on the available evidence, its certainty, and key judgments using the Grading of Recommendations Assessment, Development and Evaluation framework. New guidelines ...

The researchers reported that Scheuer stage score increased significantly with histological stage and GLOBE score. The GLOBE score of patients with primary biliary cholangitis (PBC) before treatment ...

Awareness of the key symptoms of NF1 can help in early diagnosis. A young male patient was diagnosed with neurofibromatosis type 1 (NF1) after undergoing detailed clinical investigations, according to ...

In the pivotal LUNA 3 trial, durable platelet response at week 25 was achieved by 23% of patients with rilzabrutinib compared with 0% with placebo. The US Food and Drug Administration (FDA) has ...

Kerrie Walters, who has MS, and her service dog, Wooldridge, at home in Grants Pass, Oregon (Credit: Jennifer Butler Photography) Kerrie Walters first heard of PoNS in a chance encounter with TV ...